PHIO

Phio is a pre-revenue, clinical-stage RNAi biotech, and the numbers read exactly like one: zero product revenue in any year shown, a FY2025 net loss of $8.70M, operating loss of $9.22M, and -$7.98M of operating cash burn. The accumulated deficit sits at -$155M against just 11.6M shares — the tell of repeated capital raises and reverse splits (FY2024 diluted EPS was -$9.08). ROE is -43.2%. This is a company that has never turned research into cash and won't for years, if ever.

What keeps this off 'avoid' is the balance sheet and the price. Cash is $21.0M against only $1.34M of total liabilities and no long-term debt (liabilities/equity 0.07x), leaving $20.1M of equity. At $1.00 the entire company is worth ~$11.6M — roughly 0.55x net cash. You are, on paper, buying the drug program for less than nothing, with the cash pile itself (up 291% YoY after a raise) funding roughly 2.5 years of burn at the current -$8M rate. That is a genuine floor, and it is rare.